Senior Post Doctoral Scientist
I have joined the Emerging Pathogens Group of Prof Lambe in February 2021 when still part of the Jenner Institute. Here, I worked as a senior immunologist to oversee the COVID trial vaccine team testing immune responses induced by the vaccine against SARS-CoV-2, ChAdOx1 nCoV-19. In particular, the group focused on the magnitude and longevity of cellular and antibody responses after vaccination, both in adults and in kids. Alongside, we were engaged with research on SARS-CoV-2 variants of concern.
Since March 2022, the Lambe group has joined OVG. Here, I continue the work on COVID-19 vaccine trials and I am involved in the delivery of MERS and other vaccine trials.
Previously, I joined the prostate cancer vaccine program at the Jenner Institute in September 2013. Working on a EU funded project to develop an effective vaccine against prostate cancer, we have started and completed a phase I clinical trial in low-intermediate risk prostate cancer patients receiving viral vectored vaccines targeting the tumour associated antigen 5T4.
Subsequently, we have run a phase I/II clinical trial in intermediate risk and advanced metastatic prostate cancer patients receiving the same vaccines in combination with PD-1 checkpoint blockade.
My work has also included comparative immunogenicity and efficacy assessments of a range of new and old cancer antigens in pre-clinical models of prostate cancer using viral vectored vaccines and checkpoint inhibitors. These studies aimed at the identification of the most effective antigen(s) and combination therapies for further clinical development.
I have studied biology at "Roma Tre" University in Rome and obtained my PhD degree at the University of Duisburg-Essen in the summer of 2013.
Li G, Cappuccini F, Marchevsky NG, Aley PK, Aley R, Anslow R, Bibi S, Cathie K, Clutterbuck E, Faust SN, Feng S, Heath PT, Kerridge S, Lelliott A, Mujadidi Y, Ng KF, Rhead S, Roberts H, Robinson H, Roderick MR, Singh N, Smith D, Snape MD, Song R, Tang K, Yao A, Liu X, Lambe T, Pollard AJ; COV006 study team. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.
Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA, Bara A, Bittaye M, Broadhead S, Brown A, Brown H, Cappuccini F, Cooney E, Dejnirattisai W, Dold C, Fairhead C, Fok H, Folegatti PM, Fowler J, Gibbs C, Goodman AL, Jenkin D, Jones M, Makinson R, Marchevsky NG, Mujadidi YF, Nguyen H, Parolini L, Petersen C, Plested E, Pollock KM, Ramasamy MN, Rhead S, Robinson H, Robinson N, Rongkard P, Ryan F, Serrano S, Tipoe T, Voysey M, Waters A, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Screaton GR, Winston A, Hill AVS, Gilbert SC, Pollard AJ, Fidler S, Fox J, Lambe T, Watson MEE, Song R, Cicconi P, Minassian AM, Bibi S, Kerridge S, Singh N, Green CM, Douglas AD, Lawrie AM, Clutterbuck EA. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. Published Online June 18, 2021. doi.org/10.1016/S2352-3018(21)00103-X
F Cappuccini, J Kopycinski, R Tanner. Chapter 13: Therapeutic vaccines. Drug Discovery and Development E-Book: Technology in Transition. Raymond G Hill, Duncan Richards. Elsevier Health Sciences, 16 May 2021.
KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, R Morter, A Flaxman, D Wright, D Bellamy, M Bittaye, C Dold, NM Provine, J Aboagye, J Fowler, SE Silk, J Alderson PK Aley, B Angus, E Berrie, S Bibi, P Cicconi, EA Clutterbuck, I Chelysheva, PM Folegatti, M Fuskova, CM Green, D Jenkin, S Kerridge, A Lawrie, AM Minassian, M Moore, Y Mujadidi, E Plested, I Poulton, MN Ramasamy, H Robinson, R Song, MD Snape, R Tarrant, M Voysey, MEE Watson, AD Douglas, AVS Hill, SC Gilbert, AJ Pollard, T Lambe, Oxford COVID Vaccine Trial Group. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5.
M Voysey, SA Costa Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, B Angus, VL Baillie, SL Barnabas, QE Bhorat, S Bibi, C Briner, P Cicconi, AM Collins, R Colin-Jones, CL Cutland, TC Darton, K Dheda, CJA Duncan, KRW Emary, KJ Ewer, L Fairlie, SN Faust, S Feng, DM Ferreira, A Finn, AL Goodman, CM Green, CA Green, PT Heath, C Hill, H Hill, I Hirsch, SHC Hodgson, A Izu, S Jackson, D Jenkin, CCD Joe, S Kerridge, A Koen, G Kwatra, R Lazarus, AM Lawrie, A Lelliott, V Libri, PJ Lillie, R Mallory, AVA Mendes, EP Milan, AM Minassian, A McGregor, H Morrison, YF Mujadidi, A Nana, PJ O'Reilly, SD Padayachee, A Pittella, E Plested, KM Pollock, MN Ramasamy, S Rhead, AV Schwarzbold, N Singh, A Smith, R Song, MD Snape, E Sprinz, RK Sutherland, R Tarrant, EC Thomson, M Estée Török, M Toshner, DPJ Turner, J Vekemans, TL Villafana, MEE Watson, CJ Williams, AD Douglas, AVS Hill, T Lambe, SC Gilbert, AJ Pollard, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, S Belij-Rammerstorfer, D Bellamy, S Bibi, M Bittaye, EA Clutterbuck, C Dold, SN Faust, A Finn, AL Flaxman, B Hallis, P Heath, D Jenkin, R Lazarus, R Makinson, AM Minassian, KM Pollock, M Ramasamy, H Robinson, M Snape, R Tarrant, M Voysey, C Green, AD Douglas, AVS Hill, T Lambe, SC Gilbert, AJ Pollard, Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A, Meier A, Schmidt G, Harrop R, Protheroe A, MacPherson R, Kennish S, Morgan S, Vigano S, Romero PJ, Evans T, Catto J, Hamdy F, Hill AVS, Redchenko I. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. Journal for ImmunoTherapy of Cancer 2020;8:e000928. doi: 10.1136/jitc-2020-000928
Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget. 2017 Jul 18;8(29):47474-47489.
Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016 Jun;65(6):701-13.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Ogbe A. et al, (2022), JCI Insight, 7
Ogbe A. et al, (2021)
McAuliffe J. et al, (2021), J Immunother Cancer, 9